Radius publishes data on its research in breast cancer in a variety of scientific or medical journals. Below are select articles relating to the development of our clinical pipeline.

January 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
J Clin Oncol. 2021; Jan 29 [Online ahead of print]. Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P.

September 2020
A Phase 1b Study Evaluating the Effect of Elacestrant Treatment on Estrogen Receptor Availability and Estradiol Binding to the Estrogen Receptor in Metastatic Breast Cancer Lesions using 18F-FES PET/CT Imaging.
Breast Cancer Research. 2020;22:97. Jager A, deVries EGE, Menke-van der Houven van Oordt CW, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P.

July 2020
Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, a Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
European Journal of Drug Metabolism and Pharmacokinetics. 2020;45:675-689. Conlan MG, de Vries EFJ, Glaudemans AWJM, Wang Y, Troy S.

December 2019
Elacestrant (RAD1901) Exhibits Anti-Tumor Activity in Multiple ER+ Breast Cancer Models Resistant to CDK 4/6 Inhibitors.
Breast Cancer Res. 2019; 21(146). Patel HK, Tao N, Lee K, Huerta M, Arlt H, Mullarkey T, Troy S, Arteaga CL, Bihani T.

August 2019
EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer.
Future Oncol. 2019; 15(28):3209-3218. Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG.

December 2017
Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Clin Cancer Res. 2017;23(24):17608-17620. Yu Z, He S, Wang D, Patel HK, Miller CP, Brown JL, Hattersley G, Saeh JC.

May 2017
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-Derived Xenograft Models.
Clin Cancer Res. 2017;23(16):4793-4804. Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, Purandare DM, Hattersley G, Garner F.

October 2015
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Anticancer Drugs. 2015;26(9):948-56. Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G.